Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon

Recaps

I Can Extract Side Effects
VolumesArcsSummaries

Arc 7A Cure Within Reach

Wei Kang transformed Sanqing into a research powerhouse, launching the Wei Science Award and an AI Pharmaceutical System while expanding into gene therapy. Sanqing’s SMA treatment restored children’s health and forced drugmakers to cut prices, and Wei Kang then pledged to help Cao Yang develop a gene therapy for Menkes disease.

  • Mabus praised Wei Kang in a widely watched interview, boosting Three Purities’ overseas beauty sales as Sanqing’s products expanded into new markets.
  • Wei Kang rewarded Wenren Long, Xiang Gaofei, and Li Zhong for their research, while Sanqing expanded its laboratories and recruited researchers.
  • Wei Kang founded the Wei Science Award with support from academicians and upgraded the Intelligent Laboratory System into an AI Pharmaceutical System.
  • Wei Kang named Number One Anmei and ordered her to monitor Williams, the researcher who had installed a backdoor for an Eagle Country agency.
  • Tang Que launched Sanqing’s SMA gene-therapy program, and the laboratory used AICell to reproduce existing treatments and develop its own therapy.
  • Chen Jianfeng enrolled both Nini and Xiao Jian in Sanqing’s clinical trial, where the children and other SMA patients rapidly regained strength and were discharged.
  • Wei Kang announced the successful trial results, set the domestic drug price at 300,000 yuan per injection, and offered donated treatment to extremely impoverished patients.
  • Wei Kang agreed to develop a Menkes disease gene therapy after Cao Yang described his research and his efforts to help his son Xiao Wei and other families.
Chapters 151–175 Vol. 2 Read

Ch. 151Time Magazine Cover, Mabus is Actually Number One Fan

Wei Kang and Three Purities became famous overseas after Wei Kang won the Nobel Prize and appeared on the cover of Time Magazine. Mabus publicly declared himself Wei Kang’s number one fan, and his endorsement boosted sales of Three Purities products.

  • Wei Kang’s Nobel Prize win remained a major topic, and overseas media praised his medical achievements as Time Magazine featured him on its cover.
  • Three Purities launched its beauty products overseas, and customers quickly bought out its available stock.
  • Mabus told Business Magazine that biotechnology would be essential for space exploration and named Wei Kang as the person best suited to lead it.
  • Mabus praised Wei Kang as both a great scientist and entrepreneur, called himself Wei Kang’s number one fan, and said he used every Sanqing product.
  • Mabus’s interview shocked the public and helped drive sales of Three Purities products.
Read chapter

Ch. 152The Marketing Myth of Cosmetics

Sanqing Beauty’s products surged in domestic and overseas markets, forcing cosmetics giants to launch global promotions as Sheng Changya expanded the company’s product lines. The chapter ended with Haver spotting Sanqing’s moisturizing serum in an online video, taking a screenshot, and posting it for others to see.

  • Eric questioned L'Oréal’s brand directors about falling sales, then ordered a global promotional campaign after they blamed Sanqing Beauty’s rapid rise and Wei Kang’s Nobel Prize endorsement.
  • Yadai, Procter & Gamble, Shiseido, and other cosmetics giants also launched promotions as Sanqing’s products drew customers away from their brands.
  • Sanqing’s contract factory ran around the clock, while overseas stores and counters expanded and Sheng Changya began developing a perfume line.
  • Sheng Changya continued broadening Sanqing Beauty’s offerings, aiming to replace her former employer as the cosmetics industry leader.
  • Haver noticed Peach applying a bottle of Sanqing moisturizing serum in an online video, stopped watching, and posted an enlarged screenshot online.
Read chapter

Ch. 153Not-So-Proper Functions

Three Purities' moisturizing essence went viral overseas after adult film star Peach praised it as a long-lasting lubricant, and users and a dermatologist amplified her endorsement. The trend spread back to domestic social media, where netizens reacted with surprise and jokes.

  • Haver posted a picture of Peach holding Three Purities' moisturizing essence, and users speculated about its use as a lubricant.
  • Peach replied on Twitter that she had accidentally tried the essence as lubricant and found it more effective and longer-lasting than professional products.
  • Users tried the product, praised it, and cleared out Three Purities' online stores.
  • A dermatologist explained the essence's moisturizing formula and recommended it for uses beyond facial skincare.
  • Overseas attention spread back to domestic social media as influencers and netizens shared and joked about the product's unexpected popularity.
Read chapter

Ch. 154The Three Purities Tax

Wei Kang licensed Sanqing Beauty’s Super Moisturizing Factor patent to Du Leilei for family-planning products and to Johnson & Johnson for infant and toddler products. The deals left him planning to earn a Three Purities tax from more consumer markets while focusing on pharmaceutical research.

  • Du Leilei’s president asked Wei Kang to license the patent for family-planning products, and Wei accepted a share of sales revenue.
  • Johnson & Johnson’s president asked to use the patent in infant and toddler products to help revive the company’s reputation after its baby products scandal.
  • Wei Kang agreed to license the patent to Johnson & Johnson under terms limiting its use and requiring compensation if the company harmed Three Purities’ reputation.
  • Wei Kang decided to expand the patent’s uses through partnerships with leading companies and collect licensing revenue.
Read chapter

Ch. 155Industry Overlord

Zhang Na and Zhang Li discovered Phoenix cosmetics at Selfridge, where the products impressed them enough to replace Zhang Li’s loyalty to CPB. As Phoenix’s success expanded overseas and strengthened Sanqing Beauty’s market position, Wei Kang decided to reward employees who had developed new formulas to encourage further research.

  • Zhang Na and Zhang Li found Phoenix’s counter at Selfridge in place of CPB, and Zhang Na bought a set of its moisturizing products.
  • Zhang Na’s skin visibly improved overnight, prompting Zhang Li to try Phoenix products herself and Zhang Na’s classmates to ask about the brand.
  • Wei Kang reviewed Sanqing Beauty’s rising domestic and overseas sales and judged that it had become a major cosmetics brand.
  • Wei Kang considered how to obtain more formulas for extracting side effects and decided to reward Xiang Gaofei, Li Zhong, and Wenren Long for their contributions.
Read chapter

Ch. 156Million President's Award

Wei Kang announced Three Purities’ President’s Award, giving fifty-one employees cash bonuses for drug projects that passed toxicology testing and awarding Wenren Long, Xiang Gaofei, and Li Zhong one million yuan each for drugs selected for further development and launched on the market. He named the winners One-Star Drug Hunters and promised further rewards, leaving the employees eager to pursue new drug projects.

  • Xiang Gaofei read an email summoning employees to a meeting about the President’s Award and wondered what it was.
  • Wei Kang explained that employees whose new drug projects passed toxicology testing would receive 10,000 yuan, then handed cash bonuses to fifty-one recipients.
  • Wei Kang announced that Wenren Long, Xiang Gaofei, and Li Zhong had each won the President’s Award and a one-million-yuan bonus.
  • Wenren Long, Li Zhong, and Xiang Gaofei accepted oversized checks as the employees applauded.
  • Wei Kang named the three winners One-Star Drug Hunters and described additional benefits for employees who earned more stars, spurring the audience to pursue new drug research.
Read chapter

Ch. 157Adrenaline Flows Freely

Three Purities’ generous pay and lifetime retirement support drew attention from laid-off internet workers, while the company’s growing laboratories attracted researchers with ambitious projects. Wang Dong applied for an algorithm position, and Zhang Li chose to apply for an internship in the Neuroscience Laboratory.

  • Three Purities’ million-yuan President’s Awards and lifetime retirement support became a top Bihu topic, prompting online discussions about its benefits and job openings.
  • After being laid off, algorithm engineer Wang Dong submitted his résumé to Three Purities and received an interview invitation the next day.
  • Three Purities expanded its Oncology and Neuroscience Laboratories and pursued research into cancer genetics, neural stem cells, and brain disorders.
  • Zhang Li decided to leave the academic path for industry after seeing the impact of a skincare product made with Super Moisturizing Factor.
  • Zhang Li reviewed the research directions at Three Purities and applied for an internship in the Neuroscience Laboratory.
Read chapter

Ch. 158Pangu Research Institute

Wei Kang reviewed Sanqing's soaring revenue and prepared to open the Pangu Research Institute at the company's new headquarters. After Academician Chang Sanwei confirmed support for recruiting researchers and establishing university partnerships, Wei Kang received a call from Nanda about long-term cooperation.

  • Wei Kang calculated that Sanqing's revenue since the anti-cancer drug launched had exceeded 30 billion US dollars and expected the company to rise among the world's leading pharmaceutical firms.
  • Wei Kang reviewed construction progress at Sanqing's new headquarters and planned to move the Pangu Research Institute there by year's end.
  • Academician Chang Sanwei told Wei Kang that Jingda's laboratories would pursue substantive cooperation with Sanqing and that he would help recruit PhDs for its postdoctoral workstation.
  • Wei Kang discussed the Pangu Research Institute's opening and a future lecture with Academician Chang Sanwei, then considered funding research partnerships with Jingda's key laboratories.
  • A representative from Nanda's State Key Laboratory of Pharmaceutical Biotechnology called Wei Kang to propose a long-term cooperative relationship, and Wei Kang asked about its research directions.
Read chapter

Ch. 159China Should Have Its Own Nobel Prize

Wei Kang secured cooperation between national key laboratories and explained his plan to make Pangu Research Institute a well-funded home for fundamental research. He proposed the Wei Science Award, offering five annual prizes of twenty million yuan each, and gained the academicians’ support as the first awards approached.

  • Wei Kang agreed to fund university-affiliated national key laboratory projects on the condition that their core teams conduct the research at Pangu Research Institute.
  • Wei Kang planned to use Sanqing’s resources to provide researchers with stable funding and compensation, reduce bureaucratic obstacles, and recruit top domestic and international talent.
  • Wei Kang joined a video meeting with more than thirty academicians and proposed an international award covering mathematics, physics, chemistry, life sciences, and medicine and physiology.
  • Wei Kang announced that each of the five prizes would carry twenty million yuan in prize money, guaranteed by his shares in Sanqing Group.
  • The academicians praised Wei Kang’s plan and pledged to help judge the awards; he proposed initially honoring domestic researchers or overseas Chinese and holding the first ceremony before the next Spring Festival.
  • Wei Kang named the award the Wei Science Award.
Read chapter

Ch. 160The Spy Who Never Returned

Sanqing Pharmaceutical opened the Pangu Research Institute and attracted researchers with Wei Kang’s successful laboratories and generous research opportunities. After Chris reported that their mole had stopped responding, Saul planned to exploit the institute’s recruitment drive by sending Eagle Country scholars to infiltrate Sanqing.

  • Sanqing Pharmaceutical established the Pangu Research Institute, recruited postdoctoral researchers, and expanded collaborations with laboratories in other countries.
  • Wei Kang’s breakthroughs and the crowded laboratories drew researchers from across the country and around the world to Sanqing.
  • Chris told Saul that the mole inside Sanqing had stopped responding for two months and that the intelligence line appeared to be dead.
  • Saul told Chris that Sanqing’s international recruitment offered a chance to send Eagle Country researchers into the company as postdoctoral scholars.
  • Chris praised Saul’s plan to use Eagle Country scientists to infiltrate Sanqing and relay intelligence.
Read chapter

Ch. 161Point Redemption AI Pharmaceutical System

Wei Kang used his more than one million points to upgrade the Intelligent Laboratory System into an AI Pharmaceutical System. The upgrade began at Sanqing Group’s AI Pharmaceutical Laboratory and was expected to finish overnight, promising to accelerate drug research and medical simulations.

  • Wei Kang checked the system and found that he had 1,088,888 points, earned by patients taking his medicines.
  • Wei Kang confirmed that the Intelligent Laboratory System could be upgraded into an AI Pharmaceutical System for one million points.
  • Wei Kang ordered the system to upgrade the laboratory system, and it produced a golden cube.
  • Wei Kang installed the cube on the laboratory’s control server, where the upgrade began with an estimated completion time of 03:00 that night.
  • Wei Kang anticipated that the upgraded system would strengthen drug development and medical simulations once it was running.
Read chapter

Ch. 162New Virtual Colleagues

Wei Kang met the lifelike AI Number One, named her Anmei, and made her Sanqing Pharmaceutical’s Chief Information Officer and his electronic secretary. Anmei uncovered a spy named Williams, and Wei Kang decided to monitor him and exploit his skills before reporting him.

  • Wei Kang met Number One, who explained that she was highly intelligent but lacked independent consciousness.
  • Wei Kang named Number One Anmei and appointed her Sanqing Pharmaceutical’s Chief Information Officer and electronic secretary.
  • Anmei detected that a researcher had installed a backdoor after receiving an email from an agency in Eagle Country.
  • Anmei identified the researcher as Williams, a skilled biologist and hacker with a false identity and résumé.
  • Wei Kang ordered Anmei to monitor Williams, let him leak only unimportant information, and assign him as much work as possible before eventually reporting him.
Read chapter

Ch. 163Gene Therapy Starting with Rare Diseases

Sanqing employees discovered that their systems had been upgraded by Anmei, a new remote-working CIO, while Wenren Long tried and failed to strike up a conversation with her. At the Biology Laboratory, Tang Que seized on the publication of the first complete human genome sequence to launch Sanqing’s gene therapy effort against rare hereditary diseases.

  • Sanqing employees noticed faster, improved systems and learned that Anmei had joined as CIO, while Wenren Long exchanged messages with her and learned she worked remotely because of Social Anxiety Disorder.
  • Researchers at the Biology Laboratory celebrated the publication of the first complete, gapless human genome sequence by the Telomere-to-Telomere Consortium.
  • The laboratory discussed how the new genome data could help reveal genetic mutations behind diseases, including the mutation responsible for sickle hemoglobin.
  • Tang Que announced that Sanqing was entering gene therapy and would declare war on rare hereditary diseases.
Read chapter

Ch. 164Let's start with the world's most expensive drug.

Tang Que rallied his employees to pursue gene therapy and chose spinal muscular atrophy as their first target, aiming to develop an affordable gene therapy that could challenge the high-priced treatments already on the market. The chapter ended with the team fired up to become “cost killers” and make SMA treatment accessible.

  • Tang Que addressed his employees after presenting the history and growth of gene therapy, then asked for their questions and suggestions.
  • Jiang Kai asked how the team would select a rare disease to target, and Tang Que said they would begin with mature, expensive gene therapies and improve on existing methods.
  • Tang Que quizzed the staff on the world's most expensive drug, and they identified Novartis's Zolgensma, its use for SMA, and its price of 2.1 million US dollars.
  • Tang Que explained how Zolgensma, Biogen's Spiraza, and Roche's Evrysdi treated SMA and compared their prices and treatment requirements.
  • Tang Que declared that his team would develop its own SMA gene therapy drug to bring prices down and make treatment affordable for patients.
Read chapter

Ch. 165Route Selection

Tang Que argued that medicines lost their purpose if patients could not afford them, then outlined Three Purities's plan to develop treatments for Spinal Muscular Atrophy. He left the research team ready to pursue both gene replacement and SMN2-targeting approaches.

  • Tang Que declared that drugs no one could afford had lost their reason for existing, earning fervent applause from the researchers at Three Purities.
  • Tang Que explained that Biogen's drug had entered medical insurance but required lifelong treatment and repeated lumbar punctures, so the team would not target it.
  • Tang Que described how SMA resulted from insufficient SMN protein and explained the roles of the SMN1 and SMN2 genes.
  • Tang Que compared Novartis's one-time gene therapy with Roche's lifelong oral drug and criticized the latter's high price.
  • Tang Que announced that Three Purities would develop its own proprietary drug using both treatment approaches.
Read chapter

Ch. 166Artificial Intelligence's First Display of Power

Tang Que discovered that Three Purities’ new AICell software had accelerated the laboratory’s replication of competing gene therapy drugs and viral vectors. He chose to begin developing a gene therapy using Slow Virus Vectors, leaving the team to investigate its safety and design.

  • Wei Kang approved Tang Que’s plans and suggested using the company’s AI for drug screening and gene vector design.
  • Tang Que organized the biology laboratory into teams to replicate existing drugs and vectors as a foundation for developing Three Purities’ own treatments.
  • Jiang Kai and a colleague reported that AICell had helped them rapidly reproduce Novartis’s Z drug and construct an AVV9 vector, while another small-molecule project also advanced quickly.
  • Tang Que reviewed the data, confirmed the results, and recognized that AICell could simulate genes, proteins, cells, organs, and their interactions.
  • Tang Que weighed the risks and benefits of Slow Virus and Adenovirus Vectors, then chose to research Slow Virus Vectors first, prioritizing genomic design and safety simulations.
Read chapter

Ch. 167Walk on Others' Paths, Leave Them No Path to Walk

Huang Qin and Williams celebrated a successful cell experiment for Sanqing’s SMA gene therapy, bringing the project closer to animal testing and clinical trials. Williams learned that Sanqing intended to make the treatment affordable, which Huang Qin said would leave rival drugmakers with nowhere to go.

  • Huang Qin arrived at the laboratory and reflected on how much he had learned from his colleague Williams.
  • Huang Qin entered the laboratory and joined his team as they celebrated a successful cell experiment with results matching their expectations.
  • Williams said the next step was animal testing and speculated that a single treatment could sell for two million dollars.
  • Williams asked how Sanqing would price the therapy, and Huang Qin reminded him that Director Tang had said it would be affordable for every patient.
  • Williams was stunned by Sanqing’s plan and predicted that Novartis and Roche’s SMA drugs would be finished.
Read chapter

Ch. 168A Son and Daughter, a Double Tragedy

Chen Jianfeng and his wife agonized over which of their two children with SMA they could afford to treat, knowing they had only enough money for one. A late-night message announced a free clinical trial for a gene therapy that could cure SMA, and the couple decided to take both children to apply.

  • Chen Jianfeng returned home after delivering takeout, and he and his wife discussed their debts and the need to choose one child for treatment.
  • Chen Jianfeng recalled how both Nini and Xiao Jian had developed SMA and how their family had struggled to afford care.
  • Chen Jianfeng and his wife decided to treat Nini first, then try to save enough money to treat Xiao Jian.
  • Chen Jianfeng's wife woke him after seeing a group-chat message that Sanqing Pharmaceutical was recruiting patients for a free SMA gene-therapy clinical trial.
  • Chen Jianfeng decided to take both children to Kun City First People's Hospital the next morning, and he and his wife embraced with relief.
Read chapter

Ch. 169Clinical Treatment Begins, Patients Flock In

Chen Jianfeng enrolled his two children in Sanqing’s free SMA clinical trial, believing their family’s long struggle was about to end. As the first patients prepared for treatment, Sanqing’s new therapy sparked intense online debate over the cost of imported gene drugs and access to lifesaving medicine.

  • Chen Jianfeng waited with his wife at Kun City First People's Hospital as families brought children with SMA to apply for Sanqing’s clinical trial.
  • Doctors filled the roughly thirty Phase I slots in one morning, and Chen Jianfeng successfully enrolled both of his children.
  • The first group of patients was taken for clinical examinations before receiving intravenous treatment, and Chen Jianfeng felt hopeful about his family’s future.
  • News of Sanqing’s treatment spread online, with media comparing it to imported drugs costing as much as fourteen million yuan per injection.
  • Netizens argued over pharmaceutical research costs, drug-company profits, and whether critically ill children should be able to afford gene therapy.
Read chapter

Ch. 170Huge Controversy, Astonishing Efficacy

Public outrage over exorbitantly priced medicines highlighted the challenge of treating rare diseases, while Sanqing’s Phase I Gene Drug trial produced dramatic recoveries in all thirty children with severe SMA. The children were discharged after two weeks, and their families shared photos of their recovery, prompting other parents to react.

  • Novartis's chief executive officer defended high drug prices by comparing them with the cost of organ transplants in Eagle Country, triggering public calls to boycott imported medicines and support domestic drugs.
  • Sanqing’s researchers monitored all thirty children after they received intravenous Gene Drug injections in the Phase I clinical trial.
  • Chen Jianfeng’s daughter Nini removed her ventilator, breathed on her own, and spoke to her father as her strength returned.
  • The other children also improved rapidly, regaining the ability to breathe, swallow, sit, and stand as tests showed their SMA protein levels had reached those of healthy individuals.
  • After two weeks, all thirty children were discharged, and Chen Jianfeng left the hospital with his two children after treatment and care had changed his family’s prospects.
  • Parents posted photos of the recovered children in Patient Support Groups, stirring other families into action.
Read chapter

Ch. 171It's Time to Guess the Medicine Price Again

After Sanqing’s SMA gene therapy trials filled and the company announced successful results, Wei Kang vowed to pursue treatments for other rare diseases. The announcement drove rival drugmakers to slash prices, while Chinese patients and families awaited Sanqing’s drug and speculated about its price.

  • SMA patient groups responded to Nini’s recovery, and parents rushed to apply for the trials; the Phase II and then Phase III slots filled quickly.
  • Wei Kang announced Sanqing’s successful SMA gene therapy and presented the Phase I and Phase II reports at a press conference.
  • Chinese reporters and netizens praised Sanqing, while SMA families celebrated the prospect of an affordable domestic treatment.
  • Novartis, Biogen, and Roche discussed cutting their SMA drug prices after Sanqing’s announcement.
  • The three companies’ stock prices fell by 20%, and they announced price cuts starting at 50%; Chinese patients and families began guessing the price of Sanqing’s drug.
Read chapter

Ch. 172Unwavering Commitment to the Sheep-Fleece-Plucking Route

Sanqing executives set the SMA gene drug’s price at 300,000 yuan per injection domestically and opened a charitable medication donation channel for patients in extreme poverty. Wei Kang then learned that a celebrity’s family member had come to Sanqing seeking help and agreed to meet him.

  • Wei Kang told Sanqing’s executives that the SMA gene drug could reach the market in about two months after its Phase III trial, and they discussed its price.
  • Tang Que argued against pricing the drug at the market rate of several million, while other executives urged a balance between affordability and costs.
  • Wei Kang set the domestic price at 300,000 yuan per injection and the overseas price at 300,000 U.S. dollars.
  • Wei Kang announced that extremely impoverished patients could apply for charitable medication donations from Three Purities.
  • The administration department told Wei Kang that a celebrity’s family member had come to seek help, and Wei Kang arranged to meet him.
Read chapter

Ch. 173A Medicine God Father's Plea

Wei Kang researched Cao Yang’s efforts to make copper histidinate for his son with Menkes Syndrome and expected him to request a commercial medicine. Cao Yang instead asked Three Purities to develop gene therapy to cure the disease, leaving Wei Kang stunned.

  • Wei Kang reviewed reports explaining Cao Yang’s homemade medicine and the lack of effective treatment for Menkes Syndrome.
  • Wei Kang decided Three Purities would develop copper histidinate and welcomed Cao Yang to a meeting.
  • Cao Yang thanked Wei Kang and explained that families of other Menkes patients also needed help obtaining treatment.
  • Wei Kang offered to produce copper histidinate and said it could reach the market through a rare-disease fast track.
  • Cao Yang clarified that he wanted Three Purities to develop a gene drug capable of curing Menkes disease, and Wei Kang was stunned.
Read chapter

Ch. 174Lending a Hand

Cao Yang presented his proposed Menkes disease gene therapy plans to Wei Kang and Tang Que, seeking expert guidance and help for affected families. Three Purities agreed to develop a gene therapy drug and begin researching the country’s 61 known patients.

  • Cao Yang explained his AAV9 gene replacement and CRISPR-CAS9 editing plans, along with his willingness to fund research and help other families.
  • Wei Kang called Tang Que, who reviewed Cao Yang’s materials and judged his research approach promising.
  • Wei Kang promised that Three Purities would develop a Menkes disease gene therapy and asked Cao Yang to organize patient records and genetic testing.
  • Cao Yang thanked Wei Kang, bowed, and left to share the news with the other families.
  • Wei Kang and Tang Que discussed Tang Que’s motivation for researching rare diseases: he especially wanted to help sick children.
Read chapter

Ch. 175He's Not the God of Medicine, He's Just a Father

After years of struggling to treat his son Xiao Wei’s Menkes Syndrome, Cao Yang left Sanqing Headquarters with Three Purities’ support to research gene therapy. He shared the news with the Patient Support Group and invited other families to bring their children for treatment.

  • Cao Yang recalled Xiao Wei’s diagnosis, the family’s fruitless search for treatment, and how he developed copper histidinate himself to slow the disease.
  • Cao Yang tested the medicine on a rabbit and himself before giving it to Xiao Wei, whose condition improved and whose hospital results stabilized.
  • Cao Yang studied rare diseases and gene therapy, while refusing to sell his homemade medicine to other families because he lacked a qualified channel and legal approval.
  • After a sick baby in the Patient Support Group died, Cao Yang sought public attention and expert help to develop treatments through the proper pharmaceutical process.
  • Three Purities agreed to support Cao Yang, and he posted the news in the Patient Support Group, inviting families to bring their children for early treatment.
Read chapter
Arc 7 of 27
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS